Mereo Biopharma Group PlcMereo Biopharma Group Plc
Mereo Biopharma Group Plc

Mereo Biopharma Group Plc

MREO
Health Care·Biotechnology

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

United Kingdom
Market cap
$60.7MNo data
Revenue
$500KNo data
Net income
$-41.9M+3.2% YoY
Free cash flow
$-31M+7.6% YoY

Market

Listed stock
MREOPriceNasdaq
Loading…Loading…1Y

Financial performance

Revenue
$500KNo data
Operating income
$-40.1M+15.3% YoY
Net income
$-41.9M+3.2% YoY
Free cash flow
$-31M+7.6% YoY

Revenue, profit & cash trend

Revenue
Operating income
Net income
Free cash flow
Reference
Revenue: 2021 $45.6M, 2022 $0, 2023 $10M, 2024 $0, 2025 $500K. Operating income: 2021 $-26M, 2022 $-54.4M, 2023 $-28.4M, 2024 $-47.4M, 2025 $-40.1M. Net income: 2021 $15.9M, 2022 $-42.2M, 2023 $-29.5M, 2024 $-43.3M, 2025 $-41.9M. Free cash flow: 2021 $-7.2M, 2022 $-48.8M, 2023 $-21.1M, 2024 $-33.5M, 2025 $-31M. Reference line: Reference at $0.

Growth & profitability

Revenue growth
No dataNo data
Gross margin
No dataNo data
Operating margin
No dataNo data
FCF margin
No dataNo data

Earnings power over time

Operating income
Net income
Free cash flow
Operating income: 2021-12-31 $-26M, 2022-12-31 $-54.4M, 2023-12-31 $-28.4M, 2024-12-31 $-47.4M, 2025-12-31 $-40.1M. Net income: 2021-12-31 $15.9M, 2022-12-31 $-42.2M, 2023-12-31 $-29.5M, 2024-12-31 $-43.3M, 2025-12-31 $-41.9M. Free cash flow: 2021-12-31 $-7.2M, 2022-12-31 $-48.8M, 2023-12-31 $-21.1M, 2024-12-31 $-33.5M, 2025-12-31 $-31M

Growth heatmap

2022202320242025CAGR
Revenue
-100.0%
No data
-100.0%
No data
-67.6%
Gross profit
-95.1%
+711.5%
-107.5%
+71.4%
No data
Operating income
-109.1%
+47.8%
-66.7%
+15.3%
No data
Free cash flow
-576.6%
+56.7%
-58.7%
+7.6%
No data

Earnings quality

Operating cash flow
$-31M+5.7% YoY
Net income
$-41.9M+3.2% YoY
Free cash flow
$-31M+7.6% YoY
Diluted EPS
No dataNo data

Cash conversion quality

Operating cash flow
Free cash flow
Net income = 100%
Operating cash flow: 2025-12-31 74%, 2024-12-31 76%, 2023-12-31 72%, 2022-12-31 116%, 2021-12-31 -41%. Free cash flow: 2025-12-31 74%, 2024-12-31 78%, 2023-12-31 72%, 2022-12-31 116%, 2021-12-31 -45%. Reference line: Net income = 100% at 100%.

Per-share economics

Diluted EPS
Latest
No data
FCF / share
Latest
No data
Diluted shares
Latest
No data

Financial flexibility

Cash & equivalents
No dataNo data
Total debt
No dataNo data
Net debt
No dataNo data
Current ratio
No dataNo data

Cash Coverage of Debt

Cash / Total debt
No data

Returns

Return on equity
No dataNo data
Return on assets
No dataNo data
Return on invested capital
No dataNo data
Asset turnover
No dataNo data

Return on capital

No data

Valuation

Price to earnings
No dataNo data
Price to sales
No dataNo data
EV / EBITDA
No dataNo data
Free cash flow yield
No dataNo data

Valuation vs its own 5Y history

Metric
Own five-year range
Current
Own 5Y median
Position in own range
Price to earnings
No data
No data
No data
No data
Price to sales
No data
No data
No data
No data
EV / EBITDA
No data
No data
No data
No data
Free cash flow yield
No data
No data
No data
No data